Association of TERT (rs2736098 and rs2736100) genetic variants with elevated risk of hepatocellular carcinoma: a retrospective case-control study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
09
01
2023
accepted:
23
10
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is an inflammatory problematic issue with higher mortality among different ethnic populations. The telomerase reverse transcriptase (TERT) gene has an imperative role in the proliferation of various cancerous illnesses, particularly HCC. Moreover, the TERT (rs2736098 and rs2739100) variants were correlated with the HCC susceptibility and telomere shortening, but with unconvincing outcomes. The main purpose of this outward work is to assess the correlation between these significant variants within the TERT gene and the elevated risk of HCC with the aid of various computational bioinformatics tools. This study included 233 participants [125 cancer-free controls and 108 HCC patients] from the same locality. In addition, 81.5% of HCC patients were positive for HCV autoantibodies, while 73.1% of HCC patients were positive for cirrhotic liver. Genomic DNA of the TERT (rs2736098 and rs2736100) variants were characterized utilizing the PCR-RFLP method. Interestingly, the frequencies of TERT (rs2736098*A allele) and TERT (rs2736100*T allele) conferred a significant correlation with increased risk of HCC compared to healthy controls (p-value = 0.002, and 0.016, respectively). The TERT (rs2736098*A/A) genotype indicated a definite association with positive smoking and splenomegaly (p-value < 0.05), while the TERT (rs2736100*T/T) genotype observed a significant difference with higher levels of HCV autoantibodies (p-value = 0.009). In conclusion, this significant work confirmed the contribution of the TERT (rs2736098*A and rs2736100*T) alleles with elevated risk of HCC progression and telomere shortening among Egyptian subjects.
Identifiants
pubmed: 37884663
doi: 10.1038/s41598-023-45716-w
pii: 10.1038/s41598-023-45716-w
pmc: PMC10603040
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Autoantibodies
0
TERT protein, human
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18382Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2022 Feb 05;14(3):
pubmed: 35159075
Nucleic Acids Res. 2016 Jan 4;44(D1):D877-81
pubmed: 26657631
Oncol Rep. 2021 Aug;46(2):
pubmed: 34278503
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Arab J Gastroenterol. 2012 Jun;13(2):49-53
pubmed: 22980591
J Clin Exp Hepatol. 2022 May-Jun;12(3):841-852
pubmed: 35677513
Oncotarget. 2017 Apr 4;8(14):23120-23129
pubmed: 28416747
Oncogene. 2019 Aug;38(34):6172-6183
pubmed: 31285550
Front Immunol. 2020 Nov 19;11:589929
pubmed: 33329574
Tumour Biol. 2015 Feb;36(2):841-7
pubmed: 25296732
World J Gastroenterol. 2015 Aug 21;21(31):9328-36
pubmed: 26309358
J Pers Med. 2023 Jun 06;13(6):
pubmed: 37373948
Urol Oncol. 2019 May;37(5):301.e1-301.e10
pubmed: 30738744
Gene. 2021 Feb 15;769:145223
pubmed: 33059023
Biomedicines. 2022 Mar 17;10(3):
pubmed: 35327497
Cancers (Basel). 2021 Apr 30;13(9):
pubmed: 33946181
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722302
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
J Med Virol. 2021 Nov;93(11):6278-6291
pubmed: 34289138
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
BMC Res Notes. 2014 Dec 10;7:895
pubmed: 25491902
Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):74-9
pubmed: 23392802
Gene. 2022 Jul 20;832:146585
pubmed: 35597526
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Signal Transduct Target Ther. 2022 Jan 26;7(1):24
pubmed: 35078970
DNA Cell Biol. 2019 Sep;38(9):915-921
pubmed: 31429604
J Hepatol. 2021 May;74(5):1155-1166
pubmed: 33338512
Liver. 1996 Oct;16(5):293-7
pubmed: 8938628
Hum Mutat. 2019 Sep;40(9):1292-1298
pubmed: 31228310
Cancers (Basel). 2020 Oct 25;12(11):
pubmed: 33113831
Asian Pac J Cancer Prev. 2014;15(19):8197-201
pubmed: 25339005
Fam Cancer. 2017 Jan;16(1):83-90
pubmed: 27631816
J Biochem Mol Toxicol. 2022 Mar;36(3):e22963
pubmed: 34783119
J Cancer Res Ther. 2021 Nov;17(5):1202-1208
pubmed: 34850768
Arch Physiol Biochem. 2017 Dec;123(5):279-285
pubmed: 28452232
Asian Pac J Cancer Prev. 2021 Apr 01;22(4):1279-1285
pubmed: 33906323
Zhonghua Yu Fang Yi Xue Za Zhi. 2011 Jul;45(7):593-6
pubmed: 22041560
World J Gastrointest Oncol. 2021 Dec 15;13(12):1919-1938
pubmed: 35070033
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:334-9
pubmed: 25661537
JHEP Rep. 2021 Nov 24;4(2):100410
pubmed: 35079699
N Engl J Med. 2005 Apr 7;352(14):1413-24
pubmed: 15814878
J Clin Pathol. 2019 Apr;72(4):281-284
pubmed: 30696697
J BUON. 2016 Mar-Apr;21(2):491-7
pubmed: 27273963
Biochem Genet. 2022 Feb;60(1):241-266
pubmed: 34181135
Nat Genet. 2009 Feb;41(2):221-7
pubmed: 19151717
Cell. 1993 Oct 22;75(2):387-98
pubmed: 8402920
Nucleic Acids Res. 2022 Apr 22;50(7):3764-3776
pubmed: 35323972
Genet Test Mol Biomarkers. 2015 Dec;19(12):692-7
pubmed: 26501986